Logo

Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past CO… read more

Healthcare

Biotechnology

4 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$13.04

Price

+0.93%

$0.12

Market Cap

$1.986b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$205.216m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$121.229m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.82

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$179.536m

$496.637m

Assets

$317.101m

Liabilities

$84.370m

Debt
Debt to Assets

17.0%

-0.9x

Debt to EBITDA
Free Cash Flow

-$82.808m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases